A Biotech ETF in the Middle of a Profit/Peril Market
March 03, 2020 at 08:00 AM EST
The liver diseases known as NASH, the primary cause of transplants of that vital organ, should be on investors’ radars and the ALPS Medical Breakthroughs ETF ( SBIO ) is the ETF perhaps best situated to capitalize on what could become an almost $10 billion market.